Compare Impinj Inc (PI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs ResMed Inc. — how do they compare? Impinj Inc trades at $188.02 (market cap $5.84B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 5.4× Impinj Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Impinj Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and ResMed Inc. for 51 Days on average.
| PI | RMD | |
|---|---|---|
Market Cap | $5.84B | $31.78B |
Volume | 14,433 | 1,128,382 |
Sector | Technology | Health |
52-Week High | $241.91 | $277.88 |
52-Week Low | $91.34 | $182.82 |
Typical Hold Time | 22 Days | 51 Days |
Enterprise Value | $5.97B | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $191.04, up 3.81% today, showing strong momentum with a bullish technical signal from moving averages. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.86 exceeding expectations. However, the company remains unprofitable with a net income margin of -7.26% for 2026. Analyst consensus is strongly positive with 16 buy ratings and a $178.83 price target, though the current price exceeds this target. Recent news highlights the CFO's stock sale and participation in industry conferences.
The outlook for PI is mixed; strong revenue growth and bullish analyst sentiment support upside, but profitability challenges and high valuation ratios pose risks. Investment opportunity lies in the company's positioning in RFID technology, while key risks include sustained losses and competitive pressures. The stock's proximity to resistance at $192 suggests near-term volatility.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
